EyeGene Inc (185490)

Currency in KRW
1,432
-17(-1.17%)
Closed·
185490 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,4191,448
52 wk Range
1,1823,905
Key Statistics
Bid/Ask
1,427.00 / 1,432.00
Prev. Close
1,449
Open
1,445
Day's Range
1,419-1,448
52 wk Range
1,182-3,905
Volume
163.77K
Average Volume (3m)
401.73K
1-Year Change
-54.9454%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
185490 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Biotechnology industry

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
19/03/2026
EPS / Forecast
-288.48 / --
Revenue / Forecast
774M / --
EPS Revisions
Last 90 days

EyeGene (185490) Income Statement & Profits

Compare 185490 to Peers and Sector

Metrics to compare
185490
Peers
Sector
Relationship
P/E Ratio
−3.9x−12.6x−0.5x
PEG Ratio
0.160.000.00
Price/Book
1.1x3.0x2.6x
Price / LTM Sales
17.4x7.6x3.2x
Upside (Analyst Target)
-176.2%48.8%
Fair Value Upside
Unlock10.6%6.9%Unlock

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

FAQ

What Is the EyeGene (KOSDAQ: 185490) Share Price Today?

The EyeGene stock price today is 1,432 KRW.

What Stock Exchange Does EyeGene (185490) Trade On?

EyeGene is listed and trades on the KOSDAQ.

What Is the Ticker (Stock Symbol) for EyeGene?

The stock symbol (also called a 'ticker') for EyeGene is "185490."

What Is the Current EyeGene Market Capitalisation?

As of today, EyeGene (KOSDAQ: 185490) market cap is 61.91B KRW.

What Is EyeGene's (185490) Earnings Per Share (TTM)?

The EyeGene EPS is currently -562 (Trailing Twelve Months).

Is 185490 a Buy or Sell From a Technical Analyst Perspective?

Based on today's EyeGene moving averages and other technical indicators, the daily buy/sell signal for 185490 stock is Strong Sell.

How Many Times Has EyeGene Stock Split?

EyeGene has split 2 times. (See the 185490 stock split history page for full effective split date and price information.)

What is the current trading status of EyeGene (KOSDAQ: 185490)?

As of 01/05/2026, EyeGene (185490) is trading at a share price of 1,432 KRW, with a previous close of 1,449 KRW. The stock has fluctuated within a day range of 1,419 KRW to 1,448 KRW, while its 52-week range spans from 1,182 KRW to 3,905 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.